密度 | 0.990-0.999 |
---|---|
熔点 | 81-86 °C |
外观性状 | Powder or Flakes | Yellow |
折射率 | 1.4500 |
储存条件 |
内衬塑料袋的麻袋包装。贮存于干燥、阴凉通风处 |
稳定性 |
如果遵照规格使用和储存则不会分解 |
水溶解性 | Soluble in diethyl ether, alkali, chloroform. Slightly soluble in boiling ethanol. Insoluble in water. |
更多 |
1. 性状:棕色至浅黄色脆性蜡,具有树脂状断面,微有气味 2. 密度(g/mL 25oC):0.99 3. 相对蒸汽密度(g/mL,空气=1):未确定 4. 熔点(oC常压):83-91 5. 沸点(oC,常压):未确定 6. 沸点(oC,5.2kPa):未确定 7. 折射率(n20/D):1.4500 8. 闪点(oC,):未确定 9. 比旋光度(o):未确定 10. 自燃点或引燃温度(oC):未确定 11. 蒸气压(kPa,25oC):未确定 12. 饱和蒸气压(kPa,60oC):未确定 13. 燃烧热(KJ/mol):未确定 14. 临界温度(oC):未确定 15. 临界压力(KPa):未确定 16. 油水(辛醇/水)分配系数的对数值(25℃):未确定 17. 爆炸上限(%,V/V):未确定 18. 爆炸下限(%,V/V):未确定 19. 溶解性(mg/mL) :不溶于水。溶于热乙醇、热乙醚、热氯仿、四氯化碳、油类 |
巴西棕榈蜡毒性英文版
|
个人防护装备 |
Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter |
---|---|
安全声明 (欧洲) |
24/25 |
危险品运输编码 | NONH for all modes of transport |
WGK德国 | 3 |
由巴西蜡棕(Copernicia ceriferra)的叶和叶芽(存在于表面)提取精制而得
Sun protection enhancement of titanium dioxide crystals by the use of carnauba wax nanoparticles: the synergistic interaction between organic and inorganic sunscreens at nanoscale. Int. J. Pharm. 322(1-2) , 161-70, (2006)
Carnauba wax is partially composed of cinnamates. The rational combination of cinnamates and titanium dioxide has shown a synergistic effect to improve the sun protection factor (SPF) of cosmetic prep…
|
|
In vitro erythemal UV-A protection factors of inorganic sunscreens distributed in aqueous media using carnauba wax-decyl oleate nanoparticles. Eur. J. Pharm. Biopharm. 65(1) , 122-5, (2007)
This paper describes the in vitro photoprotection in the UV-A range, i.e. 320-400 nm obtained by the use of carnauba wax-decyl oleate nanoparticles either as encapsulation systems or as accompanying v…
|
|
Wax-incorporated emulsion gel beads of calcium pectinate for intragastric floating drug delivery. AAPS PharmSciTech 9(2) , 571-6, (2008)
The purpose of this study was to prepare wax-incorporated pectin-based emulsion gel beads using a modified emulsion-gelation method. The waxes in pectin-olive oil mixtures containing a model drug, met…
|
|
MFCD00130724 |
EINECS 232-399-4 |